Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Treasury Shares (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Treasury Shares for 4 consecutive years, with $6.3 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 38.73% to $6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Dec 2025, up 38.73% year-over-year, with the annual reading at $6.3 million for FY2025, 38.73% up from the prior year.
  • Treasury Shares hit $6.3 million in Q4 2025 for Taysha Gene Therapies, up from $6.3 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $6.3 million in Q4 2025 to a low of $34673.0 in Q2 2023.
  • Historically, Treasury Shares has averaged $2.9 million across 4 years, with a median of $1.3 million in 2022.
  • Biggest five-year swings in Treasury Shares: plummeted 97.41% in 2023 and later soared 13258.91% in 2024.
  • Year by year, Treasury Shares stood at $1.3 million in 2022, then plummeted by 70.18% to $375044.0 in 2023, then surged by 1112.97% to $4.5 million in 2024, then surged by 38.73% to $6.3 million in 2025.
  • Business Quant data shows Treasury Shares for TSHA at $6.3 million in Q4 2025, $6.3 million in Q3 2025, and $6.3 million in Q2 2025.